The discovery of the involvement of the RANK-RANKL signalling pathway has led to treatment of GCTB with RANK inhibitors, such as the human monoclonal antibody Denosumab which binds to RANK and so blocks osteolysis, inhibits tumour growth and helps restore bone density [23]. Here, TNFRSF11A is linked to neoplasm.